ورود
مقالات فارسیISIکنفرانسهاژورنالها

Histopathological Evaluation of Protective Effect of Telmisartan against Radiation-Induced Bone Marrow Injury

محل انتشار: مجله فیزیک و مهندسی پزشکی، دوره: 12، شماره: 3
سال انتشار: 1401
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 53

فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:
https://civilica.com/doc/1892645

شناسه ملی سند علمی:

JR_JBPE-12-3_007

تاریخ نمایه سازی: 30 دی 1402

چکیده مقاله:

Background: Radiation-induced hematopoietic suppression and myelotoxicity can occur due to the nuclear accidents, occupational irradiation and therapeutic interventions. Bone marrow dysfunction has always been one of the most important causes of morbidity and mortality after ionizing irradiation. Objective: This study aims to investigate the protective effect of telmisartan against radiation-induced bone marrow injuries in a Balb/c mouse model.Material and Methods: In this experimental study, male Balb/c mice were divided into four groups as follow: group ۱: mice received phosphate buffered saline (PBS) without irradiation, group ۲: mice received a solution of telmisartan in PBS without irradiation, group ۳: mice received PBS with irradiation, and group ۴: mice received a solution of telmisartan in PBS with irradiation. A solution of telmisartan was prepared and administered orally at ۱۲ mg/kg body weight for seven consecutive days prior to whole body exposing to a single sub-lethal dose of ۵ Gy X-rays. Protection of bone marrow against radiation induced damage was investigated by Hematoxylin-Eosin (HE) staining assay at ۳, ۹, ۱۵ and ۳۰ days after irradiation. Results: Histopathological analysis indicated that administration of telmisartan reduced X-radiation-induced damage and improved bone marrow histology. The number of different cell types in bone marrow, including polymorphonuclear /mononuclear cells and megakaryocytes significantly increased in telmisartan treated group compared to the only irradiated group at all-time points. Conclusion: The results of the present study demonstrated an efficient radioprotective effect of telmisartan in mouse bone marrow against sub-lethal X-irradiation.

کلیدواژه ها:

Radiation ، Ionizing ، Radioprotector ، Bone Marrow ، Telmisartan

نویسندگان

- -

PhD Candidate, Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

- -

PhD, Department of Medical Imaging and Radiation Sciences, Faculty of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

- -

PhD Candidate, Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

- -

PhD, Department of Nuclear Medicine, Imam khomeini Hospital complex, Tehran University of Medical Sciences, Tehran, Iran

- -

PhD Candidate, Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

- -

MSc, Radiotherapy-Oncology Center, Yas Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

- -

PhD, Biomaterials Group, Pharmaceutical Sciences Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Xiao M, Whitnall MH. Pharmacological countermeasures for the acute radiation ...
  • Ko S, Chung HH, Cho SB, Jin YW, et al. ...
  • Calvi LM, Frisch BJ, Kingsley PD, et al. Acute and ...
  • López M, Martín M. Medical management of the acute radiation ...
  • Zhang X, Xing X, Liu H, Feng J, et al. ...
  • Kamran MZ, Ranjan A, Kaur N, Sur S, Tandon V. ...
  • Mun G-I, Kim S, Choi E, Kim CS, Lee Y-S. ...
  • Davis TA, Landauer MR, Mog SR, et al. Timing of ...
  • Moulder J, Fish B, Cohen E. Treatment of radiation nephropathy ...
  • Medhora M, Gao F, Jacobs ER, Moulder JE. Radiation damage ...
  • Yusuf S, Diener H-C, Sacco RL, et al. Telmisartan to ...
  • Al-Hejjaj WK, Numan IT, Al-Sa’ad RZ, Hussain SA. Anti-inflammatory activity ...
  • Goyal S, Bharti S, Bhatia J, et al. Telmisartan, a ...
  • Eslami H, Sharifi AM, Rahimi H, Rahati M. Protective effect ...
  • Hosseinimehr SJ. Trends in the development of radioprotective agents. Drug ...
  • Remuzzi A, Remuzzi G. Potential protective effects of telmisartan on ...
  • Abraham HMA, White CM, White WB. The comparative efficacy and ...
  • Suman S, Maniar M, Fornace AJ, Datta K. Administration of ...
  • Vaupel D, McCoun D, Cone EJ. Phencyclidine analogs and precursors: ...
  • Underwood W, Anthony R. AVMA Guidelines for the Euthanasia of ...
  • Zhang C, Lin J, Cui J, Li B, et al. ...
  • Lu X, Nurmemet D, Bolduc DL, et al. Radioprotective effects ...
  • Zhang P, Du J, Zhao H, Cheng Y, et al. ...
  • Sato T, Kinoshita M, Yamamoto T, Ito M, et al. ...
  • Li D, Tian Z, Tang W, Zhang J, Lu L, ...
  • Simonnet AJ, Nehmé J, Vaigot P, Barroca V, et al. ...
  • Dong L, Yang Y, Lu Y, Lu C, Lv J, ...
  • Zhao L, Wang Y, Shen H-l, Shen X-d, et al. ...
  • Li XH, Fu D, Latif NH, Mullaney CP, Ney PH, ...
  • Davis TA, Clarke TK, Mog SR, Landauer MR. Subcutaneous administration ...
  • Cristina Schwarz F, Da Silva Mansano N, Bruno Chies A, ...
  • Da Silva Mansano N, Jorge IF, Chies AB, et al. ...
  • Cavalim Vale AP, Dos Santos G, Da Silva, et al. ...
  • Charrier S, Michaud A, Badaoui S, et al. Inhibition of ...
  • Liu J-M, Lawrence F, Kovacevic M, Bignon J, et al. ...
  • Haznedaroglu IC, Öztürk MA. Towards the understanding of the local ...
  • Hubert C, Savary K, Gasc J-M, Corvol P. The hematopoietic ...
  • Arab HH, Al-Shorbagy MY, Abdallah DM, Nassar NN. Telmisartan attenuates ...
    • نمایش کامل مراجع